Cros

PreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical Development

Retrieved on: 
星期二, 二月 7, 2023

Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organization (CRO) to complete the following.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organization (CRO) to complete the following.
  • Construction of a clinical development plan for Phase 1 through pivotal Phase 3 studies.
  • PreveCeutical shall commence the clinical development with ICON in Q1 2023 and work with regulators to seek any potential fast track provisions as we believe that a non-addictive pain analgesic will meet the requirements due to the global abuse of painkillers currently available.
  • PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "Moving forward as PreveCeutical transitions from an R&D company into clinical development, it is our priority to select the best partner for this development.

The University of California and Foundery Sign Master Agreement to Translate Novel Discoveries into Transformational Immunotherapies

Retrieved on: 
星期四, 二月 9, 2023

The master agreement is structured to enable UCSF researchers to propose candidate drug targets or compelling biology relevant to the identification, prevention, treatment or amelioration of human diseases with underlying immune dysfunction.

Key Points: 
  • The master agreement is structured to enable UCSF researchers to propose candidate drug targets or compelling biology relevant to the identification, prevention, treatment or amelioration of human diseases with underlying immune dysfunction.
  • Foundery’s team of highly experienced and accomplished scientists subsequently conduct translational research on prioritized candidate targets in Foundery’s internal laboratories.
  • The master agreement is designed to enhance collaboration and develop impactful therapeutics between UCSF, participating scientists, and Foundery.
  • They receive financial rewards if our work on their programs is successful and also benefit from the overall success of Foundery’s portfolio.

SomaLogic announces Certified Site expansion through world-class multiomics initiative with Group 42 Healthcare

Retrieved on: 
星期二, 一月 31, 2023

BOULDER, Colo., Jan. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced the expansion of its SomaLogic™ Certified Site program through a recently-launched, world-class proteomics initiative with Group 42 Healthcare (G42), an artificial intelligence and cloud computing company.

Key Points: 
  • BOULDER, Colo., Jan. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced the expansion of its SomaLogic™ Certified Site program through a recently-launched, world-class proteomics initiative with Group 42 Healthcare (G42), an artificial intelligence and cloud computing company.
  • As part of the agreement between the two entities G42 will be the first certified site in the Middle East.
  • The SomaLogic Certified Site program gives labs and institutions—including academia and contract research organizations (CROs)—access to the SomaScan Assay, with more than 7,000 protein measurements per sample and up to 90 samples per assay kit.
  • SomaLogic can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample.

Suvoda 2022 Clinical Trials Surge 20% as it Expands Offerings to Include eConsent and eCOA

Retrieved on: 
星期二, 一月 17, 2023

PHILADELPHIA, Jan. 17, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, surpassed 1,000 clinical trials in 2022 as study deployments surged nearly 20%, a strong indicator that the company's practical approach to innovation is being embraced by trial sponsors and CROs. Click to tweet.

Key Points: 
  • Suvoda's expanded clinical trial offerings in 2022 were designed organically to work seamlessly on a single platform, and include important features that sponsors need to quickly and reliably conduct trials.
  • New products and features include:
    eConsent – Suvoda eConsent, which became generally available in May, offers a simplified approach to digitizing the consent management process.
  • Electronic clinical outcome assessment (eCOA) – Suvoda eCOA seeks to tackle inefficiencies common in traditional eCOA products, such as gaps in overall delivery and execution quality, time-consuming translations and localization processes, and logistics related to device management.
  • "Trial sponsors and CROs have told us they need new approaches to global clinical trials with patients at the center of the studies, and we have listened," said Jagath Wanninayake, CEO of Suvoda.

Suvoda 2022 Clinical Trials Surge 20% as it Expands Offerings to Include eConsent and eCOA

Retrieved on: 
星期二, 一月 17, 2023

PHILADELPHIA, Jan. 17, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, surpassed 1,000 clinical trials in 2022 as study deployments surged nearly 20%, a strong indicator that the company's practical approach to innovation is being embraced by trial sponsors and CROs. Click to tweet.

Key Points: 
  • Suvoda's expanded clinical trial offerings in 2022 were designed organically to work seamlessly on a single platform, and include important features that sponsors need to quickly and reliably conduct trials.
  • New products and features include:
    eConsent –Suvoda eConsent, which became generally available in May, offers a simplified approach to digitizing the consent management process.
  • Electronic clinical outcome assessment (eCOA) --Suvoda eCOA seeks to tackle inefficiencies common in traditional eCOA products, such as gaps in overall delivery and execution quality, time-consuming translations and localization processes, and logistics related to device management.
  • "Trial sponsors and CROs have told us they need new approaches to global clinical trials with patients at the center of the studies, and we have listened," said Jagath Wanninayake, CEO of Suvoda.

Clinical Trials Management System Market Worth $4.72 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
星期一, 一月 16, 2023

The key factors driving the market growth include the rising number of clinical trials, digitalization across healthcare R&D, number of decentralized trials, and product enhancements.

Key Points: 
  • The key factors driving the market growth include the rising number of clinical trials, digitalization across healthcare R&D, number of decentralized trials, and product enhancements.
  • Key Industry Insights & Findings from the report:
    The Clinical Trials Management System (CTMS) market was valued at USD 1.66 billion in 2022 and is expected to expand at a CAGR of 14.3% during the forecast period.
  • Clinical Trial Management System is one of the three applications of IQVIA's Digital Trial Management Suite.
  • Grand View Research has segmented the clinical trials management system market based on solution type, delivery mode, component, end-user, and region
    Clinical Trials Management System (CTMS) Market - Solution Type Outlook (Revenue, USD Million, 2017 - 2030)
    Clinical Trials Management System (CTMS) Market - Delivery Mode Outlook (Revenue, USD Million, 2017 - 2030)
    Clinical Trials Management System (CTMS) Market - Component Outlook (Revenue, USD Million, 2017 - 2030)
    Clinical Trials Management System (CTMS) Market - End-user Outlook (Revenue, USD Million, 2017 - 2030)

Clinical Trials Management System Market Worth $4.72 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
星期一, 一月 16, 2023

The key factors driving the market growth include the rising number of clinical trials, digitalization across healthcare R&D, number of decentralized trials, and product enhancements.

Key Points: 
  • The key factors driving the market growth include the rising number of clinical trials, digitalization across healthcare R&D, number of decentralized trials, and product enhancements.
  • Key Industry Insights & Findings from the report:
    The Clinical Trials Management System (CTMS) market was valued at USD 1.66 billion in 2022 and is expected to expand at a CAGR of 14.3% during the forecast period.
  • Clinical Trial Management System is one of the three applications of IQVIA's Digital Trial Management Suite.
  • Grand View Research has segmented the clinical trials management system market based on solution type, delivery mode, component, end-user, and region
    Clinical Trials Management System (CTMS) Market - Solution Type Outlook (Revenue, USD Million, 2017 - 2030)
    Clinical Trials Management System (CTMS) Market - Delivery Mode Outlook (Revenue, USD Million, 2017 - 2030)
    Clinical Trials Management System (CTMS) Market - Component Outlook (Revenue, USD Million, 2017 - 2030)
    Clinical Trials Management System (CTMS) Market - End-user Outlook (Revenue, USD Million, 2017 - 2030)

Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022: Featuring AGC Biologics, Lonza, Merck, Thermo Fisher & More - ResearchAndMarkets.com

Retrieved on: 
星期四, 一月 19, 2023

The "Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022: Frost Radar Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022: Frost Radar Report" report has been added to ResearchAndMarkets.com's offering.
  • As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases.
  • Contract development and manufacturing organizations (CDMOs) and CROs are expanding organically and inorganically to provide end-to-end CGT services.
  • More than 100 companies compete in the CGT CDMO marketplace globally, and most specialize in either cell therapy or gene therapy.

2 Day Seminar Quality and GMP Compliance for Virtual Companies (Pharmaceutical and Biologics Industries) (March 2-3, 2023) - ResearchAndMarkets.com

Retrieved on: 
星期三, 一月 18, 2023

The "2 Day Seminar Quality and GMP Compliance for Virtual Companies (Pharmaceutical and Biologics Industries)" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2 Day Seminar Quality and GMP Compliance for Virtual Companies (Pharmaceutical and Biologics Industries)" training has been added to ResearchAndMarkets.com's offering.
  • Today, many companies operate on an outsourcing model.
  • Most such companies are small, and may not have deep expertise in QA and GMP compliance, relying on their partners to cover those areas.
  • In this two day workshop conference you will learn the requirements and expectations of major health care regulators that are applicable to "virtual" companies.

Global Cardiac Safety Services Market Report 2022 to 2028: Increase in Research for Biosimilars and Biologics Drives Growth - ResearchAndMarkets.com

Retrieved on: 
星期三, 一月 18, 2023

The "Global Cardiac Safety Services Market Size, Share & Industry Trends Analysis Report by Type, End-user, Type of Service, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cardiac Safety Services Market Size, Share & Industry Trends Analysis Report by Type, End-user, Type of Service, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cardiac Safety Services Market size is expected to reach $1.1 billion by 2028, rising at a market growth of 11.1% CAGR during the forecast period.
  • Due to the grouping of services with an emphasis on end-to-end development, integrated services that provide cardiac safety services are generally favored over standalone services because of the peculiarity of standalone services.
  • As a result of COVID-19's vigorous promotion of its development, the market for cardiac safety services was positively affected overall.